Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hypogonadism | 2 | 2021 | 196 | 0.30 | Why? |
| Anti-HIV Agents | 6 | 2020 | 2209 | 0.27 | Why? |
| HIV Infections | 8 | 2020 | 11620 | 0.22 | Why? |
| Cobicistat | 1 | 2020 | 172 | 0.19 | Why? |
| Reproductive Behavior | 1 | 2018 | 22 | 0.18 | Why? |
| Dideoxynucleosides | 1 | 2018 | 92 | 0.18 | Why? |
| Hypokalemia | 1 | 2020 | 195 | 0.18 | Why? |
| Fibronectins | 1 | 2018 | 92 | 0.17 | Why? |
| Raltegravir Potassium | 1 | 2018 | 132 | 0.17 | Why? |
| Lamivudine | 1 | 2018 | 210 | 0.16 | Why? |
| Leishmaniasis, Visceral | 1 | 2017 | 85 | 0.16 | Why? |
| Darunavir | 1 | 2020 | 477 | 0.16 | Why? |
| Carotid Artery Diseases | 1 | 2017 | 251 | 0.13 | Why? |
| Endocarditis | 1 | 2019 | 368 | 0.13 | Why? |
| Organ Dysfunction Scores | 1 | 2019 | 1475 | 0.12 | Why? |
| Radioimmunoassay | 1 | 2010 | 25 | 0.11 | Why? |
| Testosterone | 2 | 2021 | 596 | 0.11 | Why? |
| Atherosclerosis | 1 | 2018 | 768 | 0.10 | Why? |
| Frailty | 1 | 2021 | 1432 | 0.10 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.09 | Why? |
| Social Stigma | 1 | 2018 | 1049 | 0.09 | Why? |
| Intention | 1 | 2018 | 1380 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.09 | Why? |
| Mothers | 1 | 2018 | 1624 | 0.08 | Why? |
| Carotid Intima-Media Thickness | 2 | 2018 | 179 | 0.08 | Why? |
| Respiration, Artificial | 3 | 2021 | 22116 | 0.08 | Why? |
| HIV-1 | 2 | 2020 | 3365 | 0.08 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.07 | Why? |
| Spain | 5 | 2020 | 15545 | 0.06 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.06 | Why? |
| Brain Chemistry | 1 | 2021 | 49 | 0.06 | Why? |
| Drug Therapy, Combination | 3 | 2020 | 7268 | 0.06 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.06 | Why? |
| Transplant Recipients | 1 | 2017 | 4982 | 0.05 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.05 | Why? |
| Risk Factors | 8 | 2021 | 71621 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| DNA, Ribosomal | 1 | 2017 | 112 | 0.04 | Why? |
| Antiprotozoal Agents | 1 | 2017 | 83 | 0.04 | Why? |
| Adult | 12 | 2021 | 244371 | 0.04 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.04 | Why? |
| Infusions, Intravenous | 1 | 2020 | 1224 | 0.04 | Why? |
| Colon | 1 | 2021 | 669 | 0.04 | Why? |
| Male | 13 | 2021 | 367725 | 0.04 | Why? |
| Microbiology | 1 | 2017 | 134 | 0.04 | Why? |
| Lipopolysaccharide Receptors | 1 | 2017 | 357 | 0.03 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.03 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.03 | Why? |
| Humans | 19 | 2021 | 930598 | 0.03 | Why? |
| Disclosure | 1 | 2018 | 423 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2020 | 1755 | 0.03 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.03 | Why? |
| Risk-Taking | 1 | 2017 | 508 | 0.03 | Why? |
| Sexual Partners | 1 | 2018 | 612 | 0.03 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.03 | Why? |
| Female | 11 | 2021 | 380317 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.03 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Outpatient Clinics, Hospital | 1 | 2017 | 523 | 0.03 | Why? |
| Aged | 7 | 2021 | 215776 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| Sex Hormone-Binding Globulin | 1 | 2010 | 57 | 0.03 | Why? |
| Follicle Stimulating Hormone | 1 | 2010 | 73 | 0.03 | Why? |
| Counseling | 1 | 2017 | 747 | 0.03 | Why? |
| Luteinizing Hormone | 1 | 2010 | 91 | 0.03 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.03 | Why? |
| HIV | 1 | 2018 | 1116 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.03 | Why? |
| Prolactin | 1 | 2010 | 68 | 0.03 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.02 | Why? |
| Age Distribution | 1 | 2019 | 3567 | 0.02 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Bacteremia | 1 | 2019 | 1372 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2019 | 5440 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.02 | Why? |
| Reference Values | 1 | 2010 | 795 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.02 | Why? |
| Family Characteristics | 1 | 2018 | 2551 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Liver | 1 | 2021 | 4007 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Echocardiography | 1 | 2019 | 3661 | 0.02 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.02 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.02 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 952 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.02 | Why? |
| Fear | 1 | 2018 | 3607 | 0.01 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.01 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.01 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.01 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.01 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2010 | 9537 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.01 | Why? |
Boix's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(126)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(66)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_